Literature DB >> 8389682

Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam.

H Ngan1, C L Lai, S T Fan, E C Lai, W K Yuen, W K Tso.   

Abstract

Eighty patients with inoperable hepatocellular carcinoma (HCC) were treated by transcatheter arterial chemoembolization using an emulsion of Lipiodol and Cisplatin. In 59 patients, gelfoam embolization was also given. The tumour size ranged from 0.5 cm to 33 cm in maximum diameter with the median diameter being 8 cm. The chemoembolization sessions were repeated every 1 1/2 to 3 months. The number of sessions the patients underwent varied from 1 to 11, with the mean number of sessions being 3.7. The HCC either disappeared completely or decreased in size in 44 patients (55%). In patients having an HCC of 12 cm or less in size, 31 out of 41 (75.6%) who had the addition of gelfoam demonstrated decrease in tumour size, while seven out of 11 (63.6%) without the addition of gelfoam demonstrated decrease in tumour size. In patients having an HCC of more than 12 cm in size, only six out of 18 (33.3%) who had the addition of gelfoam demonstrated reduction in tumour size and none of the 10 patients without the addition of gelfoam responded. Thus, HCCs of 12 cm or less in size responded better than larger ones to chemoembolization (P < 0.0001) while the addition of gelfoam enhanced the response (P = 0.039). The 1 year survival rate for the 80 patients was 53% and the 2 years survival rate was 38%. The median survival was 13 months. For patients having an HCC of 12 cm or less in size, the 1 year and 2 year survival rates were 69% and 47% respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389682     DOI: 10.1016/s0009-9260(05)81446-1

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  7 in total

1.  Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization.

Authors:  F Farinati; N De Maria; C Marafin; L Herszènyi; S Del Prato; M Rinaldi; L Perini; R Cardin; R Naccarato
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 2.  Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016.

Authors:  Stephen L Chan; Charing C N Chong; Anthony W H Chan; Darren M C Poon; Kenneth S H Chok
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

3.  Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation.

Authors:  Mike-S-L Liem; Ronnie-T-P Poon; Chung-Mau Lo; Wai-Kuen Tso; Sheung-Tat Fan
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

4.  Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT.

Authors:  Mingde Lin; Romaric Loffroy; Niels Noordhoek; Katsuyuki Taguchi; Alessandro Radaelli; Järl Blijd; Angelique Balguid; Jean-François Geschwind
Journal:  Minim Invasive Ther Allied Technol       Date:  2010-11-17       Impact factor: 2.442

Review 5.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

6.  Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Guang Chen; Da-Qing Ma; Wen He; Bao-Feng Zhang; Li-Qin Zhao
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

7.  Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma.

Authors:  S D Ryder; P M Rizzi; E Metivier; J Karani; R Williams
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.